CVS Health has announced a plan to divide its massive healthcare conglomerate into two separate, publicly traded companies by the first half of 2028 . The restructuring will detach the company's retail pharmacy operations from its insurance and pharmacy benefit management businesses.
A 2028 deadline to separrate 9,000 retail stores from Aetna
Under the proposed restructuring, one entity will retain the CVS Health name, housing the insurance provider Aetna, the pharmacy benefit manager (PBM) CVS Caremark, and subsidiaries like Oak Street Health and Signify Health. The second entity, named CVS Pharmacy, will manage the retail division's approximately 9,000 stores, its mail-order pharmacy, MinuteClinic, and the Health100 technology unit.
CVS Health CEO David Joyner indicated on CNBC that this decision was driven by increasing scrutiny from lawmakers regarding how healthcare conglomerates profit from controlling multiple stages of the medical supply chain. According to the report, the announcement caused immediate volatility in the market, with CVS shares dropping nearly 13% on Tuesday.
The $69 billion Aetna legacy and the push against vertical integration
This breakup serves as a reversal of the trend that began in 2017 when CVS agreed to acquire Aetna for $69 billion. For nearly a decade, the company has operated as a vertically integrated behemoth, a model that has increasingly drawn the ire of regulators. The report notes that the Department of Labor recently finalized a rule requiring PBMs to be more transparent with cost data and payments made to drugmakers.
The pressure is not just federal; state-level legislation has begun to target this business model. In 2025 and 2026, Tennessee and Arkansas passed laws that prohibit PBMs from owning retail pharmacies to prevent conflicts of interest. While CVS Health has challenged these specific state laws in federal court, the broader corporate split suggests the company is attempting to get ahead of an inevitable regulatory shift toward decentralization.
Why a 13% stock plunge signals investor anxiety over the split
The market reaction reflects a fear that the retail arm may struggle as a standalone business. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), suggested that CVS Pharmacy might accelerate its trend of shuttering underperforming locations, noting that the company has already closed roughly 10% of its stores in recent years.
From a competitive standpoint, Hoey argues that the split could benefit the roughly one-third of pharmacies nationwide that remain independently owned. By separating the PBM (which decides reimbursement rates) from the retail stores (which receive those rates), the move could stop CVS from acting as "the judge, the jury and the executioner" for its competitors, many of whom have been pushed toward bankruptcy, as seen with Rite Aid.
The CVS Specialty loophole and the fate of GLP-1 drug pricing
Despite the split, a critical question remains: will this actually lower prices for patients? Dr. Mariana Socal, a professor at Johns Hopkins, told the source that she does not expect prices to drop because the split fails to separate the PBM, Caremark, from the insurer, Aetna.
Furthermore, the NCPA points out a significant caveat: CVS Specialty will remain within the healthcare solutions division rather than moving to the retail pharmacy side. This means the highly profitable mail-order operations for expensive medications—including cancer treatments and GLP-1 weight-loss drugs like Ozempic—will still be tied to the PBM and insurance business. This arrangement leaves open the possibility that patient steering and rebate gaming will continue in the specialty medication market, leaving the most expensive drugs untouched by the restructuring.
Comments 0